Compare KMT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | DYN |
|---|---|---|
| Founded | 1938 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2020 |
| Metric | KMT | DYN |
|---|---|---|
| Price | $27.54 | $22.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $25.83 | ★ $36.53 |
| AVG Volume (30 Days) | 999.1K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,982,871,000.00 | N/A |
| Revenue This Year | $2.40 | N/A |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.30 | $6.36 |
| 52 Week High | $29.15 | $31.29 |
| Indicator | KMT | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 67.34 | 61.55 |
| Support Level | $25.23 | $20.44 |
| Resistance Level | $28.25 | $22.27 |
| Average True Range (ATR) | 0.85 | 1.50 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 71.56 | 98.32 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.